A dose-ranging safety and pharmacokinetics study of candesartan cilexetil in hypertensive pediatric subjects 1 to less than 6 years of age: a 4-week, multicenter, randomized, double-blind study with a 1-year, open-label, follow-up period

Trial Profile

A dose-ranging safety and pharmacokinetics study of candesartan cilexetil in hypertensive pediatric subjects 1 to less than 6 years of age: a 4-week, multicenter, randomized, double-blind study with a 1-year, open-label, follow-up period

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Essential hypertension; Secondary hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CINCH
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 82 to 125 as reported by European Clinical Trials Database.
    • 12 Feb 2010 Results published in Journal of Hypertension.
    • 12 Feb 2010 Primary endpoint 'Systolic blood pressure' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top